The Power of RNA: How Transcriptomics is Transforming Cancer Research

Transcription is the process by which a cell generates an RNA molecule (a transcript) from the genetic material stored as DNA. The field of transcriptomics quantifies and classifies RNA to better understand transient cellular states, which are important in neoplastic malignancies like cancer.

The Foundation: Early Insights from Gene Profiles

Gene profiles of oncology patients have been studied in various ways. The genetic basis of some cancers is well understood and extensively researched. One of the more successful stories comes from the treatment of chronic myelogenous leukemia, which is frequently caused by the translocation of chromosomes 9 and 22, resulting in the BCR-ABL tyrosine kinase oncogene. The identification of this translocation, later called the Philadelphia chromosome, from where it was discovered, ushered in the era of precision medicine in oncology. Imatinib, the drug which specifically targets the BCR-ABL tyrosine kinase produced from the translocation, significantly decreased annual mortality rates in CML from 10-20% to 1-2%.¹

Expanding Precision: Beyond Primary Etiology

Landmark publications resulting from clinical trials, such as NCI MATCH, have shown significant efficacy of targeting druggable driver mutations in the clinic. However, exceptions to this treatment strategy were observed, such as the resistance in colorectal cancer patients harboring the BRAF V600E mutation, compared to melanoma and other types of cancer. This provided the field with sufficient evidence that targeting the genetic profile of cancers, rather than following the standard of care based on the primary etiology, could be a practical approach.² More evidence grew with epidermal growth factor receptor mutations targeting drugs in lung cancer, and human epidermal growth factor receptor 2 targeting therapies in breast cancer.

The development and implementation of clinical genome profiling tools, such as Oncotype Dx, and cancer-specific type genome profiling tools, like MammaPrint for breast cancer, have become the standard, providing clinical guidance for providers on the risk of recurrence based on treatment paths. Many of these tools have become clinically indispensable in making treatment decisions that significantly reduce patient risk and improve prognosis. Furthermore, clinical trials show substantially better outcomes using companion diagnostics or biomarker-driven patient stratification.^{3, 4, 5}

The Rise of Transcriptomics in Clinical Trials

Clinical trials using transcriptomics, like WINTHER, PROVABES, INFORM, and PIPseq, have provided evidence that an RNA analysis of tumor tissue, compared to normal tissue, may be significant in matching patients to the right targeted therapies.^{6, 7, 8, 9} Furthermore, combining transcriptomics (RNA sequencing) with the genome profile (DNA sequencing) is especially relevant, as studies have shown that some patients have DNA mutations that are silenced at the RNA level, and this RNA degradation may also serve as a resistance mechanism in targeted therapies.^{10, 11, 12} Multiple aspects of the patient's tumor, such as the transcriptome, epigenetics, microRNA expression, and, to a lesser extent, non-coding RNAs, have demonstrated clinical linkages in predicting cancer progression and metastasis.^{11, 12, 13, 14, 15, 16}

The Future of Precision Oncology: A Multi-Omic Approach

The trajectory of cancer research and treatment is increasingly moving towards a more comprehensive, multi-omic understanding, where the dynamic landscape of the transcriptome complements the heritable information in the genome. Integrating insights from RNA analysis alongside DNA profiling provides a powerful lens into tumor biology, refining our ability to predict response, identify mechanisms of drug resistance, and guide personalized therapeutic strategies.

The quality and integrity of the biological sample is paramount, whether milliliters of blood or a small biopsy sample. In these cases, genomic purification and extraction reagents, as well as automation, play an indispensable role. Ensuring robust and consistent isolation of high-quality RNA from complex clinical specimens is the vital first step for reliable downstream analysis and unlocking the next era of precision oncology.

Related Topics